Literature DB >> 7690928

Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation.

E A Medcalf1, J Milner.   

Abstract

E6-mediated degradation of p53 is believed to play a role in the transformation of cells by high-risk types of human papillomavirus. In order to explore the structural requirements for targeting of p53 we have compared E6-mediated degradation of variant p53 forms expressed in vitro. Complete degradation was observed in samples containing monomers, dimers and higher molecular weight structures of wild-type p53, indicating that E6 targets all quaternary forms of wild-type p53. Wild-type human and murine p53s reactive with PAb 1620 (which recognizes a conformation-dependent epitope) were degraded when incubated with E6. Mutant p53 proteins were variably resistant to E6-mediated degradation, and this correlated with PAb 1620 reactivity. Thus, mutants hp53Val-154, hp53Val-266 and hp53Pro-273 (1620 degrees) were completely resistant to degradation, whereas hp53Ile-247 and hp53Trp-248 (1620+) were degraded. Mutants hp53Leu-273 and mp53Val-135, which are temperature sensitive for conformation, were completely degraded in the 1620+ form but degradation resistant in the 1620 degrees form. Although the PAb 1620+ conformation appeared important for recognition of p53 by E6, the epitope itself is unlikely to be the actual recognition target since the PAb 1620 monoclonal antibody failed to protect against E6-mediated degradation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690928

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Carcinoma of the lung: warts and all.

Authors:  A F Markham
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

2.  Increased salt concentration reversibly destabilizes p53 quaternary structure and sequence-specific DNA binding.

Authors:  S Butcher; P Hainaut; J Milner
Journal:  Biochem J       Date:  1994-03-15       Impact factor: 3.857

3.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.

Authors:  X Li; P Coffino
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma.

Authors:  Y Soini; K Nuorva; D Kamel; R Pöllänen; K Vähäkangas; V P Lehto; P Pääkkö
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

5.  Inhibition of p53 DNA binding by human papillomavirus E6 proteins.

Authors:  M S Lechner; L A Laimins
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo.

Authors:  Katia Zanier; Christine Ruhlmann; Frederic Melin; Murielle Masson; Abdellahi Ould M'hamed Ould Sidi; Xavier Bernard; Benoit Fischer; Laurent Brino; Tutik Ristriani; Vladimir Rybin; Mireille Baltzinger; Scott Vande Pol; Petra Hellwig; Patrick Schultz; Gilles Travé
Journal:  J Mol Biol       Date:  2009-11-13       Impact factor: 5.469

7.  The active form of E6-associated protein (E6AP)/UBE3A ubiquitin ligase is an oligomer.

Authors:  Virginia P Ronchi; Jennifer M Klein; Daniel J Edwards; Arthur L Haas
Journal:  J Biol Chem       Date:  2013-11-22       Impact factor: 5.157

8.  The p53 isoforms are differentially modified by Mdm2.

Authors:  Suzanne Camus; Sergio Ménendez; Kenneth Fernandes; Nelly Kua; Geng Liu; Dimitris P Xirodimas; David P Lane; Jean-Christophe Bourdon
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

9.  Generation and Characterization of Site-Specifically Mono-Ubiquitylated p53.

Authors:  Alexandra Julier; Vanessa Radtke; Andreas Marx; Martin Scheffner
Journal:  Chembiochem       Date:  2022-02-03       Impact factor: 3.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.